(burgdo,feri may be sequestered in a protective niche within the host allowing its long-term survival [ 1, 3, 4. 13] .
The Lyme disease spirochete gains entry into the host through the skin, where it spreads locally and establishes in fection [I, 3, 4) . In this study we examined whether fibro blasts, cells that are abundant in the skin, protect B. burgdor feri from the action of a clinically useful antibiotic.
ceftriaxone [I, [13] [14] [15] . _ We also examined whether the cell spirochete interaction was related to the organism's infectiv ity and whether it was specific for fibroblasts. 
Materials and Methods
Organisms. All strains and clones of B. burgdo,feri were cul tured at 32°C in modifi ed Barbour-Stoenner-Kelly (BSK) me dium formulated as previously described [ 16 ] . The c. ultures were routinely monitored by darkfield microscopy for growth and con tamination. The number of spirochetes was determined using a Petroff-Hausser bacteria counting chamber. Viability of the spirochetes was assessed by motility; nonmotile organisms were l\, considered non viable [ l 6 ]. For long-term preservation of spiro .J chetes at desired passages, aliquots of the cultures were stored at � -70°C in the presence of 15% glycerol. . .
and l 2 serial I 0-fold dilutions were made. The plates were placed in a candle jar to provide a microaerophilic environment for optimal growth of B. burgdorferi [ l, 2] and incubated at 32°C. Wells were checked weekly for the presence of spiro chetes by darkfield microscopy. Cultures were considered to contain cloned organisms when ,;;;J wells of 8 in the last vertical row that. contained spirochetes were positive. Spirochete infectivity assay. The infectivity of the B. burgdor feri strains and clones was assesse _ d by their ability � o ersist in an experimental rodent as previously descnbed 6 Spiro chetes were injected intraperitoneally into Swiss We ster mice (O. l mL. 5.0 X 10 7 live organisms/mouse). Three weeks after inoculation the mice were sacrifi ced, and the urinary bladder and spleen were cultured as previously described [ 16] . The cul tures were examined for the presence of live spirochetes every 2-4 days for I month.
MBC. For each strain and clone used in these experiments, the MBC of ceftriaxone (Rocephin; Hoffmann-La Roche, Nut ley. NJ) was determined by the broth dilution method [ 17, 18] . The concentrations of ceftriaxone tested ranged from 0.00 l to 10.0 JLg/mL. Duplicate wells of 24-well polystyrene plates con taining BSK with ceftriaxone and control wells without antibi otic were inoculated with spirochetes at 1.0 X I 0 6 viable organ isms/ml. The plates were placed in a candle jar and incubated at 32°C. After 48 h, the number of viable spirochetes in each well was determined by darkfield microscopy. and inoculations were made at l % dilution (vol/vol) in wells containing BSK without antibiotic. The plates were incubated as above and monitored for spirochetal growth over the course of 4 weeks. The MBC was the lowest concentration of ceftriaxone from which viable spirochetes were not detectable in the subculture.
Cell cultures. Human foreskin fibroblasts, mouse keratinocytes. HEp-2 cells (larynx epidermoid carcinoma cells, epithe lial-like) , Vero cells (green monkey kidney cells, fibroblast-like), and Caco-2 cells (human colon adenocarcinoma cells, epithe lial-like) were cultured in multiwell polystyrene tissue culture dishes (35-mm wells in six-well plates) in Dulbecco's modified Eagle medium (GIBCO. Gaithersburg, MD) with l 0% heat-inac tivated fetal bovine serum (FBS; HyClone Laboratories, Logan. UT) at 37°C in humidifi ed air with 5% CO 2 , except for Caco-2 cells, which were cultured in 15% FBS. Confluent cell cultures were split by treatment with trypsin-EDT A (0.05% trypsin, 0.53 mM EDT A· 4Na; GIBCO).
Coculture of spirochetes with eukaryotic cells. Spirochetes at logarithmic phase of growth were centrifuged at 9000 g at 20°C for 20 min and resuspended in RPMI 1640 tissue culture me dium (GIBCO) supplemented with I 0% heat-inactivated FBS, 1 % L-glutamine, and l O mM HEPES (pH 7.4). The supernatants of confluent cell cultures were decanted, and spirochetes were added to wells containing a monolayer or to wells without cells (2.0-5.0 X 10 7 live organisms/well) and incubated at 37°C with 5% CO 2 in humidified air. Cells and spirochetes were cocultured for 48 h. The cells were then washed twice with warm PBS, pH 7.4, fresh tissue culture medium containing ceftriaxone at l..!:J) mL was added, and the cocultures were further incubated. After 48 h, the cells were washed twice with warm PBS and lysed by adding 0.5 mL of distilled HP for 5 min. In preliminary experi ments, suspension of spirochetes in distilled HP for 5 min did not affect their viability. Adherent cells were then scraped off, and the total content of each well was inoculated into l O mL of BSK. Cultures were incubated at 32°C and monitored for the � presence of viable spirochetes every 2 or 3 days for 4 weeks. Control wells without cells but with spirochetes underwent the same procedure. Experiments were run in duplicate or triplicate.
To exclude the possibility that fi broblast products inactivated ceftriaxone and thus protected the spirochetes, ceftriaxone was dissolved (at I JLg/mL) in cell-free (filtered through 0.45 /Lm filters) fibroblast-conditioned medium (supernatant from fibro· blast monolayers obtained after 48 h in culture) and added to control wells that had spirochetes without fibroblasts .
In some experiments, fibroblasts were fixed with glutaralde hyde before addition of spirochetes. For glutaraldehyde fixation, wells with or without fibroblast monolayers were incubated with 2% glutaraldehyde (vol/vol) in PBS at 4°C for 2 h. Wells were then washed three times with PBS, and organisms were added as above.
To prepare human foreskin fibroblast lysate, fibroblast mono layers in supplemented RPMI tissue culture medium were scraped off, transferred into tubes, sonicated, and transferred back to wells. Fibroblast lysate was then cocultured with B. burgdorferi as above.
To study the survival of spirochetes over periods of antibiotic treatment >48 h, fibroblast monolayers were infected for 48 h and then treated with ceftriaxone for 3-14 days. Each day from day 3 to day 14, duplicate monolayers were washed, lysed, scraped, inoculated into BSK, and incubated at 32 °C. For mono layers that were maintained in culture for >3 days, every third day the medium containing ceftriaxone was replaced to provide the cells and spirochetes with fresh medium containing active antibiotic.
Statistics. For statistical evaluation, the x 2 test with Yates's correction was used.
Results
We fi rst determined the MBC of ceftriaxone for all strains and clones used in these studies. llllllll--------------------JID l 992 ; l 66 (August) strain and clone had an MBC of 0.1 µg/mL. Therefore, we used a concentration of ceftriaxone that was at least IO times the MBC, I µg/mL, for testing the possible protective effect of cells against the antibiotic. Table 2 . Time course of the protective effect of human fibroblasts on B. burgdorferi against the action of ceftriaxone ( l µg/mL).
We then examined whether fi broblasts would protect B. burgdorferi from the action of ceftriaxone. As shown in table I, the presence of fi broblasts completely protected the spiro chetes, which grew in culture after inoculation of the lysate \ of fibroblasts infected with strains or clones of B. burgdorferi for 2 days and then treated with ceftriaxone at I µg/mL for 2 · days. In the absence of fi broblasts, the antibiotic was effec-� tive in eliminating organisms in 43 of the 46 samples. Cellfree fi broblast-conditioned medium did not protect the spiro-
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chetes from the lethal action of ceftriaxone, suggesting that fibroblasts did not protect the organisms by inactivating the antibiotic. To further confirm the absence of a neutralizing effect of fi broblasts on ceftriaxone, fibroblast-conditioned medium that contained ceftriaxone at I µg/mL and that had been incubated as above for 48 h was tested for antibiotic concentration in a bioassay using Escherichia coli as the test organism. The concentration of ceftriaxone in fibroblast- conditioned medium was equal to that in a sample that conceftriaxone. Spirochetes cultured in the absence of cells or in tained the antibiotic in tissue culture medium that had also glutaraldehyde-treated wells did not survive. Furthermore, been incubated as above for 48 h; both samples were found fibroblast lysate (sonicated human foreskin fibroblasts) was to contain ceftriaxone at l µg/mL. (/Yo t&2yaJ tJl r 2da.,s)not protective for B. burgdorferi (table l). These findings To determine whether viable fibroblasts were needed for suggest that a living cell w� re�ed to promote survival of protection of the spirochetes from the action of ceftriaxone, the organism inthe pr esence of the antibiotic. additional culture wells with or without fibroblasts that had We also examined whether there was a relationship bebeen treated with glutaraldehyde were cocultured with B.
tween in vivo infectivity of B. burgdorferi and the ability of burgdorferi. As shown in table I, glutaraldehyde-fixed fibrothe organism to be protected from ceftriaxone by the presblasts did not protect the spirochetes from the lethal effect of ence of fibroblasts. As shown in table I, both infective (N40, ? 297, N40P6D9, 297P6E8) and noninfective (G3940A6, • 297P49C8, 297P49E8) organisms were protected from the action of the antibiotic in the presence of fibroblasts. There fore, the protective effect of fibroblasts was not directly re lated to the infectivity of the organism in the mouse model. To examine the time course of the protective effect of fi bro blasts on B. burgdorferi, we extended the treatment with cef triaxone to 14 days. As shown in table 2, spirochetes ( clone 297P6E8) were able to survive in the presence of fi broblasts even after l 4 days of ceftriaxone treatment. In the absence of fibroblasts, the antibiotic was lethal for the spirochetes.
Since B. burgdorferi do not grow in tissue culture medium, we next defined a mixed culture medium that would permit spirochetal growth and at the same time maintain viable fi broblast monolayers. In a medium consisting of 50% tissue culture medium and 50% BSK (volfvol), fibroblasts prolifer ated to 204.7% ± 42.1% and spirochetes to 144.9% ± 41.2% of the initial inoculum in 3 days. Using this medium, we examined the protective effect of fi broblasts on B. bwgdor feri. In I l of 12 cultures, spirochetes were recovered from ceftriaxone treated cocultures of spirochetes with fibroblasts. In the absence of fibroblasts, B. burgdorferi was isolated in only 1 of 12 cultures (P < .0005). Therefore, fibroblasts were (.) . .
able to protect the Lyme disease spirochete from the action of ceftriaxone in a medium that permits growth of extracellu lar organisms. To determine whether the protective effect of fi broblasts for the Lyme disease spirochete was unique, we examined the ability of different eukaryotic cell types to protect B. burgdo,feri from the action of ceftriaxone. Like human fibro blasts ( 18 positive of 20 cultures), mouse keratinocytes (8/ 8), Yero cells ( 14/ 18), and HEp-2 cells (6/7) also protected the spirochetes. However, Caco-2 cells did not exert a pro tective effect, and B. burgdorferi did not grow in any of 12 cultures (P < .0005 compared with all others).
Discussion
In the present study, fibroblasts and keratinocytes, cells that are abundant in the skin, protected Borre!ia burgdorferi from the action of an antibiotic commonly used for its eradi cation, ceftriaxone [I, [13] [14] [15] . Even at 10 X MBC of cef triaxone, as determined by the present study and as previ ously reported [ 14, 17, 18] , spirochetes cocultured with fibroblasts or keratinocytes survived after 2 days of treat ment. Protection of B. burgdorferi required viable cells, since no organisms survived in the presence of cell-free fibroblast conditioned medium, glutaraldehyde-fixed fi broblasts, or fibroblast lysate ( table I) .
Unlike our previous findings. in which infective strains of B. burgdorferi differed from noninfective ones in their ability to evade phagocytic cellslfl6!, the ability of B. burgdorferi to survive in the presence ofti6roblasts was not related to the strain 's or clone's infectivity ( table I) . This implies that the 1 ability to interact with fibroblasts is not strictly linked to the , organism's infectivity, at least when infectivity is assessed as persistence of the spirochete in the rodent model that we and others used [ 16] . One of the regimens most commonly used clinically for treatment of Lyme disease is administration of ceftriaxone for 14 days (I, 14, 15] . Our time course experiments showed that human skin fi broblasts can protect B. burgdorferi from '' examine the maximum duration of this protective effect.
!c eftriaxone for 14 days (table 2). It will be of interest to
A central question about the pathogenesis of chronic Lyme disease is whether th_ �J�ath_Q_lQgyjs relate<l_in any way to the presence of viab!UJ2irochetes. A strong suggestion that this may be the case c� from studies demonstrating �olation of B. _burg1orferi from patients many years after the initial infection. On the basis of this observation, several au thors have suggested that the organism is sequestered in pro tective niches [I, 3, 4, 13] . It has been previously demon strated that B. burgdo,feri penetrates endothelial cell ,, · -· monolayers and can be observed inside and between these cells; however, the viability of those potentially intra-and mtercellular spirochetes was not assessed �l-In a recent study, B. burgdorferi was shown to penetrate'toitured human umbilical vein endothelial cells, but the viability of the intra cellularly located spirochetes was not assessed (20] . The or ganism also has been observed inside phagocytic cells, but electron and fluorescence microscopy studies have provided evidence that it does not survive inside these cells ( 4 ].
At least three possibilities could explain our observations. First, the antibiotic could have been inactivated and there fore was not lethal for the spirochetes. This is unlikely. since ceftriaxone was lethal for B. burgdorferi in the control wells in the absence of cells (tables I and 2). Furthermore, the fibroblasts did not inactivate the antibiotic, since cell-free fibroblast-conditioned medium containing ceftriaxone was borreliacidal (table I) , and a bioassay using another organ ism showed that ceftriaxone in either tissue culture medium or fibroblast-conditioned medium was bioactive.
A second possibility is that the tissue culture medium in some of these experiments did not permit growth of B. burg dorferi and thus might have made spirochetes resistant to the cell wall-active antibiotic ceftriaxone. If this were the case, then organisms in the control wells in the absence of cells should have survived. Furthermore, we confirmed our obser vation in a medium (50% borrelial growth medium and 50% tissue culture medium) that allows growth of both the spiro chetes and the fi broblast monolayers.
A third possibility is that the organism, like other patho gens, penetrates cells and survives in them. An intracellular site of survival would provide protection, since many of the antibiotics are much less concentrated in the cells than in extracellular spaces. Also, it would be consistent with the ability to isolate B. burgdo,feri from patients with high anti body titers [2, [5] [6] [7] [8] [9] [10] [11] [12] , since the intracellular site would pro tect the spirochete from the host's immune system. Possibly fibroblasts and keratinocytes are the initial sites of this intra cellular survival. This is especially relevant in that the fi rst contact between the spirochete and the host in Lyme disease occurs in the skin. Furthermore, animal studies have shown that the skin is the optimal site for B. burgdorferi inoculation; considerably fewer organisms are needed to induce persis tent infection if inoculated intradermally than by other routes [21] . Future studies are required to precisely define the locale of the protective effect of eukaryotic cells for B. burgdo,feri as well as whether other antibiotics with different modes of action and different ability to penetrate cells, such as macrolides (e.g., erythromycin), would eliminate the Lyme disease spirochete even in the presence of cells.
